article thumbnail

Overcoming Healthcare’s Mountain of Mistrust – Part 2: Payers

Perficient: Drug Development

To recap: Part 1 of the series focused on providers This part, Part 2, focuses on payers (insurance companies) Part 3 (by Marlana Voerster ) will focus on medical-device organizations First off: the bad news in trust for payers Gallup’s polling data among U.S. But there are opportunities for advancing your position.

Nurses 52
article thumbnail

Combo ‘Polypill’ May Cut Heart Attack, Stroke Risk Up to 40%

The Pharma Data

A single pill also is cheaper to market and distribute. Yang pointed out that “the fact that it’s generic is a double-edged sword, because no big pharma company is willing to invest a lot of money in developing and marketing a polypill. If it’s more convenient together, why not?” ” Yusuf said.